The international research consortium led by Leitat had their final meeting this month in Barcelona and finalized the first prototype of the biosensor.
Â Barcelona, May 30, 2019 â€“ GLAM is a European research project that developed a sensor able to detect multiple bladder cancer biomarkers from a few drops of urine. The device, based on photonic and monoclonal antibody biosensor technologies, shows various advantages compared to current techniques: it is fast, ultra-sensitive, simple to use, portable, and cheap. The project was coordinated by Leitat and involved 9 other partners from 6 different EU countries: the Institute for Bioengineering of Catalonia (IBEC) and the Â Institute of Photonic Sciences (ICFO) in Spain, the University of Twente and Radboud University Medical Center in the Netherlands, WizSoft in Israel, the UniversitÃ© Libre de Bruxelles (ULB) and Obelis S.A. in Belgium, Novelic in Serbia, and Optocap in the UK.
During the last 4 years, the partners created a prototype of the sensor, which can detect up to 10 biomarkers in urine. This will help oncologists make better treatment decisions according to the patientâ€™s needs in a non-invasive manner for bladder cancer diagnosis. Moreover, the consortium published several papers and applied for a patent. GLAM had a budget of 4â€™835â€™586 euros, financed through the EUâ€™s Horizon 2020 research programme.
According to Francesc Mitjans, technical project coordinator at Leitat, â€œThis is a step towards truly personalized medicine in cancer. The device might allow the identification of new prognostic patterns for a better classification of patients, prognosis evaluation and treatment decision.â€
+34 93 788 23 00
+34 699 05 04 81